An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
NCT ID: NCT02128334
Last Updated: 2016-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
645 participants
OBSERVATIONAL
2013-09-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will evaluate total serum PSA and testosterone levels, Quality of Life (QoL) of patients, demographic patient data, diagnosis and diagnostic findings in patients. It will provide analysis in different subgroups of patients depending on previous hormonal treatment and anamnesis of disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
NCT01442246
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
NCT00378690
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
NCT05304169
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
NCT00220194
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
NCT03035032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with advanced prostate carcinoma
Eligard 45 mg Exposure
Subcutaneous injections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eligard 45 mg Exposure
Subcutaneous injections
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: PRINCIPAL_INVESTIGATOR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site RU34 Private Practice
Abakan, , Russia
Site RU23 Private Practice
Anapa, , Russia
Site RU33 Private Practice
Belgorod, , Russia
Site RU27 Private Practice
Irkutsk, , Russia
Site RU29 Private Practice
Irkutsk, , Russia
Site RU36 Private Practice
Izhevsk, , Russia
Site RU60 Private Practice
Kostroma, , Russia
Site RU10 Private Practice
Krasnodar, , Russia
Site RU12 Private Practice
Krasnodar, , Russia
Site RU13 Private Practice
Krasnodar, , Russia
Site RU9 Private Practice
Krasnodar, , Russia
Site RU35 Private Practice
Kursk, , Russia
Site RU1 Private Practice
Moscow, , Russia
Site RU11 Private Practice
Moscow, , Russia
Site RU14 Private Practice
Moscow, , Russia
Site RU15 Private Practice
Moscow, , Russia
Site RU2 Private Practice
Moscow, , Russia
Site RU20 Private Practice
Moscow, , Russia
Site RU3 Private Practice
Moscow, , Russia
Site RU32 Private Practice
Moscow, , Russia
Site RU4 Private Practice
Moscow, , Russia
Site RU42 Private Practice
Moscow, , Russia
Site RU44 Private Practice
Moscow, , Russia
Site RU55 Private Practice
Moscow, , Russia
Site RU56 Private Practice
Moscow, , Russia
Site RU6 Private Practice
Moscow, , Russia
Site RU61 Private Practice
Moscow, , Russia
Site RU7 Private Practice
Moscow, , Russia
Site RU71 Private Practice
Moscow, , Russia
Site RU72 Private Practice
Moscow, , Russia
Site RU8 Private Practice
Moscow, , Russia
Site RU21 Private Practice
Nizhny Novgorod, , Russia
Site RU63 Private Practice
Nizhny Novgorod, , Russia
Site RU64 Private Practice
Nizhny Novgorod, , Russia
Site RU53 Private Practice
Novosibirsk, , Russia
Site RU30 Private Practice
Omsk, , Russia
Site RU18 Private Practice
Orenburg, , Russia
Site RU66 Private Practice
Orenburg, , Russia
Site RU68 Private Practice
Oryol, , Russia
Site RU37 Private Practice
Petrozavodsk, , Russia
Site RU40 Private Practice
Ryazan, , Russia
Site RU73 Private Practice
Ryazan, , Russia
Site RU17 Private Practice
Saint Petersburg, , Russia
Site RU19 Private Practice
Saint Petersburg, , Russia
Site RU65 Private Practice
Saint Petersburg, , Russia
Site RU76 Private Practice
Saint Petersburg, , Russia
Site RU59 Private Practice
Stavropol, , Russia
Site RU25 Private Practice
Syktyvkar, , Russia
Site RU54 Private Practice
Tver', , Russia
Site RU26 Private Practice
Yekaterinburg, , Russia
Site RU43 Private Practice
Yekaterinburg, , Russia
Site RU58 Private Practice
Yekaterinburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RU-EGD-NI-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.